Bill · H.R. 3873· House(119-HR-3873)
KO Cancer Act
- Introduced
- 6/10/2025
- Last activity
- 6/10/2025 — Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Brian Fitzpatrick
- Cosponsors
- - 1 - 5
- Introduced
- In Committee
What this bill would do
The "Knock Out Cancer Act" aims to increase funding for cancer research through the National Cancer Institute. For fiscal years 2026 through 2030, it appropriates an amount equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022. These funds are intended to be in addition to other available amounts. Additionally, the bill mandates a study by the Secretary of Health and Human Services regarding the causes of cancer drug shortages. This study must include an analysis of economic reasons, supply chain failures, and drug development or approval delays. Finally, the Secretary must submit a report to Congress within one year including recommendations to address these shortages.
Yes· 3 of 4
Does this put more money into medical research?+8
The bill directly appropriates significant additional funds to the National Cancer Institute to advance cancer research.
Does this put more money into scientific research?+7
The bill provides significant new funding specifically for cancer-related scientific research through the NCI.
Does this make health care easier to get in general?+5
Increased NCI funding supports research that can improve treatment options and access to life-saving medical innovations.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Research Funding: The bill appropriates additional funds to the National Cancer Institute for fiscal years 2026 through 2030, which is intended to help the United States address cancer mortality rates and impacts on patients (Section 3).
-
Addressing Drug Shortages: The Secretary of Health and Human Services is required to study the reasons for cancer drug shortages, which includes looking into economic reasons, supply chain failures, and issues with drug development or approval (Section 4).
-
Future Recommendations: The study on drug shortages must include recommendations for addressing those shortages, which could help address issues regarding insufficient generic drugs and biosimilar biological products (Section 4).
Potential Negative Impacts for People
- No negative impacts are explicitly mentioned in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Increases Research Funding+8Improves Healthcare Access+5Reduces Prescription Drug Costs+3
- Education And Technology
- Increases Scientific Research Funding+7
- 10/10/2025
- 1 Cosponsor added.
- 9/30/2025
- 1 Cosponsor added.
- 9/15/2025
- 1 Cosponsor added.
- 8/22/2025
- 1 Cosponsor added.
- 7/25/2025
- 1 Cosponsor added.
- 6/10/2025
- Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
Robert BresnahanRepublican · Pennsylvania
Debbie DingellDemocrat · Michigan
Josh GottheimerDemocrat · New Jersey
Laura GillenDemocrat · New York
Gabe VasquezDemocrat · New Mexico
Eugene VindmanDemocrat · Virginia